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ABSTRACT
Objective Although direct-acting antiviral agents
(DAAs) have markedly improved the outcome of
treatment in chronic HCV infection, there continues to be
an unmet medical need for improved therapies in
difﬁcult-to-treat patients as well as liver graft infection.
Viral entry is a promising target for antiviral therapy.
Design Aiming to explore the role of entry inhibitors for
future clinical development, we investigated the antiviral
efﬁcacy and toxicity of entry inhibitors in combination with
DAAs or other host-targeting agents (HTAs). Screening a
large series of combinations of entry inhibitors with DAAs
or other HTAs, we uncovered novel combinations of
antivirals for prevention and treatment of HCV infection.
Results Combinations of DAAs or HTAs and entry
inhibitors including CD81-, scavenger receptor class B
type I (SR-BI)- or claudin-1 (CLDN1)-speciﬁc antibodies or
small-molecule inhibitors erlotinib and dasatinib were
characterised by a marked and synergistic inhibition of
HCV infection over a broad range of concentrations with
undetectable toxicity in experimental designs for
prevention and treatment both in cell culture models and
in human liver-chimeric uPA/SCID mice.
Conclusions Our results provide a rationale for the
development of antiviral strategies combining entry
inhibitors with DAAs or HTAs by taking advantage of
synergy. The uncovered combinations provide perspectives
for efﬁcient strategies to prevent liver graft infection and
novel interferon-free regimens.
INTRODUCTION
The current standard of care (SOC) in chronic
genotype 1 HCV infection consists of pegylated
IFN-α, ribavirin (RBV) and a protease inhibitor—
telaprevir or boceprevir.1–3 Furthermore,
direct-acting antivirals (DAAs) sofosbuvir and sime-
previr have been licensed very recently. Although
expected to revolutionise HCV treatment by offer-
ing cure in the very large majority of treated
patients,4 DAAs appear to have distinct limitations
in certain difﬁcult-to-treat patient subgroups, such
as patients with advanced liver disease, transplant,
HIV/HCV-coinfected and immune-compromised
patients.2 Hurdles in these groups include resist-
ance and side effects.2 4 Furthermore, not all geno-
types respond similar to DAA combinations and
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Signiﬁcance of this study
What is already known on this subject?
▸ Direct-acting antivirals (DAAs) increase the
response to IFN-based antiviral therapy against
HCV genotype 1 but also lead to selection of
drug-resistant HCV variants.
▸ Given their important side effects and drug–
drug interactions, DAAs against HCV are not
approved for patients undergoing liver
transplantation (LT), HCV/HIV coinfected
patients or paediatric patients.
▸ Although early clinical trials have
demonstrated impressive outcomes for
combinations of DAAs in IFN-free regimens for
treatment-naive patients, there will be a need
for novel antivirals addressing resistance,
treatment of patients with comorbidity,
co-medication or immunosuppression and
patients undergoing LT.
▸ HCV entry into target cells is a promising target
for preventive and therapeutic antiviral
strategies.
What are the new ﬁndings?
▸ Given their complementary mechanism of
action, entry inhibitors inhibit viral infection in
a synergistic manner in combination with DAAs
both in cell culture models and in human
liver-chimeric uPA/SCID mice.
▸ Synergy between entry inhibitors and DAAs or
other host-targeting agents holds promise for a
variety of possibilities of combination
therapies for prevention of HCV liver graft
infection and might be also useful for
treatment of hepatitis C.
How might it impact on clinical practice in
the foreseeable future?
▸ Novel combinations based on synergy may
widen the therapeutic arsenal against HCV
infection for prevention of liver graft infection,
treatment of difﬁcult-to-treat-patients and
provide alternatives for patients with
contraindications to particular compounds of
standard of care or future IFN-free regimens.
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high costs limit access to therapy in low-income, middle-income
and high-income countries.2 4
Among the most difﬁcult-to-treat patient groups are indivi-
duals with HCV-induced end-stage liver disease undergoing
liver transplantation (LT).1 2 Due to viral evasion from host
immune responses and absence of preventive antiviral strategies,
graft reinfection is universal. Moreover, IFN-based therapies
have limited efﬁcacy and tolerability in LT recipients.5 The use
of telaprevir and boceprevir is limited by drug–drug interactions
if combined with immunosuppressive agents.6 7 Furthermore,
emergence of resistant strains will certainly be higher in these
patients because of lower efﬁcacy of SOC and greater need for
dose adjustments.5 These challenges deﬁne a need for additional
combinations of therapeutics, ideally targeting complementary
steps of the viral life cycle, with improved efﬁcacy and safety.
A promising antiviral target complementary to targets of SOC
and DAAs is viral cell entry. HCV entry is the ﬁrst step of virus–
host cell interactions and is required for dissemination and
maintenance of infection.8 Viral entry plays an important role
in the pathogenesis of HCV infection, especially during HCV
reinfection of the graft after LT.9 10 Targets for entry inhibitors
include CD81, scavenger receptor class B type I (SR-BI), tight
junction proteins CLDN1 and occludin, epidermal growth
factor receptor (EGFR)8 11 and Nieman-Pick C1-Like 1.12 Entry
inhibitors exhibit a broad pan-genotypic activity.10 12–21 By
acting through a complementary mechanism of action (MOA),
entry inhibitors may synergistically act with SOC. To explore
the future application of entry inhibitors for combination
therapy in IFN-free regimens, we investigated the antiviral efﬁ-
cacy of entry inhibitors in combination with DAAs or other
host-targeting agents (HTAs) in state-of-the-art cell culture
models and in human liver-chimeric uPA/SCID mice.
MATERIAL AND METHODS
Cell lines
Huh7.5.1 cells and primary human hepatocyte (PHH) culture
have been described.13
Antibodies and inhibitors
CLDN1- (OM-7D3-B3),22 SR-BI- (NK-8H5-E3)14 and CD81-
speciﬁc (QV-6A8-F2C4)16 monoclonal antibodies (mAbs) have
been described. Erlotinib and dasatinib were from LC
Laboratories, and IFN-α2a and IFN-α2b were from Roche and
Merck. Alisporivir, telaprevir, boceprevir, danoprevir, simepre-
vir, daclatasvir, mericitabine and sofosbuvir were synthesised by
Acme Bioscience.
Analysis of antiviral activity of compounds and
combinations on HCV infection
Each compound was tested individually or in combination with
a second compound using the cell culture-derived HCV
(HCVcc)-Huh7.5.1 model.14 23 Production of HCVcc has been
described.13 For prophylactic/prevention combination experi-
ments, Huh7.5.1 cells were preincubated with IFN-α, DAAs or
HTAs for 1 h at 37°C before incubation for 4 h at 37°C with
HCVcc and both compounds. For therapeutic/treatment com-
bination experiments, Huh7.5.1 cells were infected with HCVcc
during 5 days to establish chronic persistent HCV infection
before adding compounds for additional 5 days.23 Viral infec-
tion was analysed by assessing luciferase activity.10 13 22
Analysis of synergy
Synergy was assessed by two independent methods: the combin-
ation index (CI)24 and/or the Prichard and Shipman method.25
A CI <0.9, 0.9–1.1 and >1.1 indicates synergy, an additive
effect and antagonism, respectively.24 For the Prichard and
Shipman method, a surface >20% above the zero plane indi-
cates synergy and a surface <20% below the zero plane indi-
cates antagonism.25 Validity of the assay and methods was
conﬁrmed by non-synergistic or antagonistic combinations.
HCV cell culture persistence assay
HCV RNA ( Jc1 or Luc-Jc1) was electroporated into Huh7.5.1
cells to establish persistent HCV infection. Then, 1% DMSO
was used to differentiate the cells and maintain them in
culture without passage for up to 20 days.26 Medium contain-
ing compounds at the indicated concentrations was replen-
ished every 4–5 days until the end of the experiment.
Luciferase activity or RT-PCR was used to monitor viral infec-
tion and viral load.27
In vivo experimentation
Human liver-chimeric uPA/SCID mice were transplanted with
PHH at 3 weeks of age by intrasplenic injection of 106 cells sus-
pended in PBS as described previously.28 Successful engraftment
was determined by measuring the human albumin (HA) concentra-
tion in the serum of transplanted mice by speciﬁc ELISA (Bethyl,
Catalogue No. E80-129). Mice with HA levels >1 mg/mL were
used for IV inoculation with HCV Jc1-containing infectious
mouse serum (6×103 IU). Eight weeks later, the mice were allo-
cated to different treatment groups. Mice received telaprevir
(300 mg/kg) or vehicle (carboxymethylcellulose 0.5%, tween-80
0.2%) per os twice a day and were intraperitoneally injected
with 500 mg of control or anti-SR-BI mAb (NK8-H5-E3) twice
a week for 2 weeks. Blood was collected by retro-orbital punc-
ture every 5–10 days under isoﬂurane anaesthesia for the deter-
mination of serum HCV RNA level and HA concentration.
Experiments were performed in the Inserm Unit 1110 animal
facility according to local laws and ethical committee approval
(AL/02/19/08/12 and AL/01/18/08/12).
Toxicity assays
Huh7.5.1 cells and PHH were incubated with compounds for
48 h and/or 5 days.22 23 Cytotoxic effects were analysed using
MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide) assay13 22 or PrestoBlue assay (Invitrogen) with ﬂavo-
piridol or anti-Fas antibody as positive controls.22 The 50%
cytotoxic concentrations (CC50) of entry inhibitors were calcu-
lated by regression analysis.
Statistical analysis
Statistical analysis and CI estimations have been run under
Bayesian paradigm. Results are given as mean and (95% credible
interval). Data were analysed by IC (50/75/90). Group compari-
sons were based on the mean difference. Normality was assessed
with a Shapiro–Wilk test. When required, data transformation
was used to reach normality. Each data set was analysed using
hierarchical (mixed) model with ﬁxed group effects and random
treatment effect as described.29 The whole data set was analysed
using a two-stage hierarchical model, with the ﬁxed group
effects and two random effects that were treatment and IC (50/
75/90), in order to take account of both levels of repeated mea-
surements. Dummy variables, representing the IC studied (50/
75/90), had also been considered as ﬁxed effects to test differ-
ences between CI in each case. For all of these models, unin-
formative priors for coefﬁcients were used: Gaussian
distributions with mean 0 and precision 0.001, gamma distribu-
tion with parameters 0.1 and 0.1 for the model precision.
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Hyperpriors for random effects were also uninformative:
normal with mean 0 and precision 0.001, and a uniform distri-
bution (0.100) for dispersion parameters. Assumption of homo-
geneous dispersions in random effects was respected.
Computations were run with R 3.00 and WinBUGS 1.4. For
each analysis, a single MCMC chain with 5000 iterations as
burn-in and 100 000 iterations was used to generate the poster-
ior distribution. Convergence was checked and present in every
case. Unless otherwise stated, results are shown as means±SEM
from three independent experiments performed in triplicate.
For the Prichard and Shipman method, one representative
experiment performed in triplicate is shown.
RESULTS
Synergy of entry inhibitors and DAAs uncovers novel
combinations for IFN-free regimens
A major effort of current drug development is to develop
IFN-free treatments based on the combination of DAAs with or
without RBV.1 Addressing these concepts, we studied the com-
bined antiviral effect of entry inhibitors with clinically licensed
protease inhibitors telaprevir,30 31 boceprevir,32 33 simeprevir34
and danoprevir—a protease inhibitor in late-stage clinical devel-
opment35 using the HCVcc cell culture model. The antiviral
effect of each molecule was tested alone or in combination to
determine the CI. Combination of telaprevir or boceprevir with
a sub-IC50 concentration of all entry inhibitors tested—which
exerts only minimal inhibition on HCV infection—resulted in
synergy with CIs of 0.48–0.71 at IC90 (ﬁgure 1A and online
supplementary table S1). Calculation of 95% credible intervals
indicates that the differences between CI values did not occur
by chance (ﬁgure 1A and online supplementary table S1).
Synergy was also observed at IC50 and IC75 (ﬁgure 1A and
online supplementary table S1). Inversely, combination of tela-
previr and boceprevir was additive (CI of 0.94, 95% credible
interval (0.84 to 1.04); ﬁgure 1A) conﬁrming the validity of the
assay. Combination of simeprevir or danoprevir with entry inhi-
bitors resulted in synergy at all inhibitory concentrations (CIs of
0.06 to 0.65 at IC90; ﬁgure 1A and online supplementary table
S1), demonstrating the relevance of adding an entry inhibitor to
improve antiviral efﬁcacy in preventing HCV infection. Highly
effective combinations included inter-alia combinations of tela-
previr with erlotinib (ﬁgure 2A), and boceprevir or simeprevir
with anti-CLDN1 mAb (ﬁgure 2B, C).
A number of NS5A and polymerase inhibitors have reached
early-stage to late-stage clinical development including clinical
licensing of the ﬁrst compounds. As the ﬁrst NS5A inhibitor,
daclatasvir36 has shown potent antiviral activity against HCV
genotype 1 in mono- and combination therapy.37 38 Marked
synergy at all inhibitory concentrations was observed for com-
bination of daclatasvir with entry inhibitors (CIs of 0.27–0.89
at IC90; ﬁgure 1B, online supplementary table S1C). Effective
combinations included inter-alia combinations of daclatasvir and
anti-SR-BI, anti-CLDN1 mAbs or erlotinib decreasing its IC50
up to 60-fold (ﬁgure 3A–C).
Figure 1 Combination of
direct-acting antivirals and entry
inhibitors results in a synergistic
activity in preventing HCV infection.
Huh7.5.1 cells were preincubated for
1 h with serial concentrations of (A)
telaprevir, boceprevir, simeprevir or
danoprevir, (B) daclatasvir or (C)
mericitabine or sofosbuvir and
0.01 mg/mL of receptor-speciﬁc
(anti-CD81, anti-SR-BI or anti-CLDN1)
mAbs or 0.1 mM protein kinase
inhibitors (erlotinib or dasatinib) before
incubation with HCVcc Luc-Jc1 in the
presence of both compounds. HCVcc
infection was analysed by luciferase
activity as described.22 The CIs at IC50,
IC75 and IC90 are indicated in online
supplementary table S1. Means±95%
credible intervals from three
independent experiments performed in
triplicate are shown.
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Finally, we investigated synergy between entry inhibitors and
the polymerase inhibitor sofosbuvir,39 which recently obtained
FDA approval and has the potential to become the cornerstone
for an efﬁcacious, all-oral combination regimen for many
HCV-infected patients.40 41 Combination of sofosbuvir with
entry inhibitors resulted in synergy at all inhibitory concentra-
tions (CIs of 0.41–0.61 at IC90; ﬁgure 1C, ﬁgure 4A, B, D, E
and online supplementary table S1). Potent combinations
included inter-alia combinations of sofosbuvir and anti-SR-BI or
anti-CLDN1 mAbs, decreasing its IC50 up to 18-fold, and com-
binations of sofosbuvir with erlotinib or dasatinib decreasing its
IC50 up to 210-fold (ﬁgure 4A,B,D,E). These data demonstrate
the potential of combining sofosbuvir with entry inhibitors to
improve its antiviral activity. Similar results were obtained when
combining mericitabine35 with entry inhibitors (CIs of 0.18–
0.68 at IC90; ﬁgure 1C and online supplementary table S1).
To further conﬁrm synergy over a broad range of concentra-
tions of two compounds, we performed combinations of each
DAA with a deﬁned entry inhibitor, testing a full checkerboard
of compound dose–response curves.25 In particular, combina-
tions of low doses of two compounds resulted in an antiviral
effect well above the expected value (ﬁgures 2D–F, 3D–F and
4C,F). These results demonstrate that adding an entry inhibitor
markedly increases the antiviral activity of different DAAs cur-
rently evaluated in IFN-free regimens, thereby deﬁning novel
antiviral combinations for further preclinical and clinical devel-
opment in IFN-free regimens.
Combination of HTAs results in a synergistic antiviral effect
It is still not clear whether DAA-based therapies will be effective
and safe in difﬁcult-to-treat populations including patients with
comorbidity, complex co-medication, immunosuppression and
patients undergoing LT. Combinations of HTAs are a promising
alternative to DAAs for IFN-sparing regimens, allowing increas-
ing the genetic barrier to resistance. The clinically most
advanced HTA is cyclophilin A inhibitor alisporivir.42
Combination of alisporivir with entry inhibitors resulted in a
marked synergy (CIs of 0.19–0.69 at IC75 and 0.06–0.50 at
IC50; ﬁgure 5D and online supplementary table S2). Effective
combinations included inter-alia alisporivir and erlotinib or
anti-CLDN1 mAb (ﬁgure 5E). Indeed, very low concentrations
of these entry inhibitors markedly increased the antiviral effect
of alisporivir by decreasing its IC50 up to 3000-fold. Synergy of
alisporivir and anti-CLDN1 mAb was conﬁrmed using the
Prichard and Shipman method (ﬁgure 5F). Taken together,
these data demonstrate the promise of combining HTAs acting
on complementary steps of the viral life cycle and open perspec-
tives for HTA-based DAA or IFN-free regimens. These combina-
tions may be of particular interest for/to patients who are
resistant to SOC, or cannot tolerate SOC or combinations of
DAAs. Furthermore, combinations of two entry inhibitors
resulted in synergy on HCVcc infection at all inhibitory concen-
trations (CIs of 0.13–0.68 at IC90; ﬁgure 5A–C and online
supplementary table S2) except for combination of anti-CLDN1
and anti-CD81 mAbs that resulted in an additive effect (CI of
0.95, 95% credible interval (0.85–1.06) at IC90; ﬁgure 5A).
Entry inhibitors potentiate the antiviral activity of IFN-α in a
synergistic manner
Since IFN-α is the key component of current SOC, we also
investigated whether HCV entry inhibitors potentiate the anti-
viral activity of IFN-α by combining an entry inhibitor with
Figure 2 Antiviral synergy of entry and protease inhibitors. Combination (A) telaprevir and erlotinib, (B) boceprevir or (C) simeprevir and
anti-CLDN1 mAb was performed as described in ﬁgure 1. (D–F) Synergy was conﬁrmed using the Prichard and Shipman method.25
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Figure 3 Synergy of entry inhibitors and daclatasvir. Combination of daclatasvir and (A) anti-SR-BI mAb, (B) anti-CLDN1 mAb or (C) erlotinib was
performed as described in ﬁgure 1. (D–F) Synergy was conﬁrmed using the Prichard and Shipman method.25
Figure 4 Entry inhibitors enhance the antiviral activity of sofosbuvir in a synergistic manner. Combination of sofosbuvir and (A) anti-SR-BI mAb,
(B) anti-CLDN1 mAb, (D) dasatinib or (E) erlotinib was performed as described in ﬁgure 1. (C, F) Synergy was conﬁrmed using the Prichard and
Shipman method.25
Hepatology
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IFN-α2a or IFN-α2b. Combination of IFN-α2a or IFN-α2b
with a sub-IC50 concentration of receptor-speciﬁc mAb resulted
in a synergistic activity at IC90 in inhibiting HCVcc infection
(CIs of 0.16–0.53) (see online supplementary ﬁgure S1 and
table S3). Synergy combining IFN-α2a or IFN-α2b with erloti-
nib has been described elsewhere.23 Synergy was also observed
at IC50 and IC75 for all combinations tested (see online
supplementary ﬁgure S1 and table S3). Conversely, in line with
previously reported data,43 combination of IFN-α2a or IFN-α2b
with sorafenib, a different protein kinase inhibitor (PKI) that inhi-
bits the antiviral effects of IFN, resulted in antagonism (CI of
1.23; 95% credible interval (1.13–1.34) and 1.27, 95% credible
interval (1.16–1.38); online supplementary ﬁgure S1A,B and
table S3), demonstrating that the observed synergies are speciﬁc
for the combinations and not related to technical issues of the
model. Calculation of 95% credible intervals indicates that the
differences between CI values did not occur by chance (see
online supplementary table S3). These data demonstrate that
entry inhibitors enhance the antiviral activity of IFN-α.
Synergy in experimental design for treatment of HCV
infection
Finally, to explore whether synergy between DAAs or HTAs and
entry inhibitors also occurs in experimental approach mimicking
treatment of chronic infection, we used a well-established design
of persistent infection.23 Similar to the prevention design shown
before, combining DAAs or alisporivir with entry inhibitors also
resulted in high synergy when compounds were added postin-
fection in chronically infected cells (ﬁgure 6) as well as in
chronically infected DMSO-differentiated hepatoma cells26
(ﬁgure 7), which are more physiologically relevant than normal
hepatoma cells. These data demonstrate the potential of com-
bining DAAs or HTAs with entry inhibitors to improve their
antiviral activity for the treatment of chronic hepatitis C.
Entry inhibitors limit viral rebound from DAA therapy
Using the cell culture model system for chronic HCV infection,
we studied whether entry inhibitors limit viral rebound follow-
ing discontinuation of DAA treatment. As shown in ﬁgure 8,
treatment of persistently HCV-infected cells with a well-
characterised and recently FDA-approved protease inhibitor,
simeprevir, resulted in a rapid reduction of viral load in a time-
dependent manner. However, an increase in viral load was
observed following withdrawal of simeprevir. In contrast, the
addition of an entry inhibitor (anti-CD81 mAb or erlotinib) at
the time of simeprevir withdrawal allowed to further decrease
the viral load, indicating that entry inhibitors limit viral rebound
from DAA therapy. Cell viability test at the end of the
Figure 5 Synergy of host-targeting agents on HCV infection. (A) Combination of receptor-speciﬁc (anti-CD81, anti-SR-BI or anti-CLDN1) mAbs and
protein kinase inhibitors (erlotinib or dasatinib) was performed as described in ﬁgure 1 and the CIs at IC50, IC75 and IC90 are indicated in online
supplementary table S2. Means±95% credible intervals from three independent experiments performed in triplicate are shown. (B) Combination of
anti-CLDN1 mAb and dasatinib (left) or erlotinib (right). (C) Synergy was conﬁrmed using the Prichard and Shipman method.25 (D) Combination of
alisporivir and entry inhibitors was performed as described in ﬁgure 1 and the CIs at IC50, IC75 and IC90 are indicated in online supplementary table
S2. Means±95% credible intervals from three independent experiments performed in triplicate are shown. (E) Combination of alisporivir with
erlotinib (left) or anti-CLDN1 mAb (right). (F) Synergy was conﬁrmed using the Prichard and Shipman method.25
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experiment demonstrated that the reduction of viral infection
was not due to cytotoxicity (table 1D).
Combination of entry inhibitors and DAAs in vivo
To assess the relevance of combining an entry inhibitor and a
DAA for treatment of HCV infection and provide experimental
evidence for a synergistic effect of entry inhibitors and DAAs
in vivo, we used human liver-chimeric uPA/SCID mice persist-
ently infected with HCVcc ( Jc1). Nine persistently infected
mice were grouped randomly to receive either telaprevir
monotherapy, anti-SR-BI mAb monotherapy, combination of
telaprevir and anti-SR-BI mAb or the control treatment for
2 weeks as described in ‘Materials and methods’. In line with
previous reports,44 telaprevir only slightly reduced viral load
of HCV genotype 2-infected mice, while anti-SR-BI
mAb-treated mice showed a reduction of HCV RNA levels of
approximately 1 log10 at the end of the treatment.
Interestingly, the combination of telaprevir and anti-SR-BI
mAb resulted in a more potent reduction of viral load at each
tested time point than the calculated sum of both monother-
apies (at d10 HCV load for the control treatment is 6.86
±0.06 log10; for telaprevir monotherapy 6.72±0.42 log10; for
anti-SR-BI mAb 6.03±0.54 log10; for combination therapy in
the responder mouse 3.71 log10), reaching more than 2 log10
in one of the mice after 10 days (ﬁgure 9A). One mouse treated
with telaprevir and anti-SR-BI mAb did not respond to treatment
(ﬁgure 9A). Stable levels of HA in the blood of mice from differ-
ent treatment groups (ﬁgure 9B) suggested that their liver func-
tion was not affected by the treatment, indicating that telaprevir
or/and anti-SR-BI mAb combination therapy did not result in
major hepatotoxicity in vivo.
Absent toxicity of combinations in PHHs and hepatoma cells
Noteworthy, the uncovered combinations did not exhibit any
detectable toxicity in PHH nor Huh7.5.1 cells, neither in short-
term or long-term infection experiments (table 1). In contrast,
anti-Fas antibody or the well-characterised kinase inhibitor ﬂa-
vopiridol resulted in easily detectable toxicity (table 1). The
50% cytotoxic concentrations (CC50) of entry inhibitors in
long-term experiments were more than 10-fold or 100-fold
higher than the therapeutic concentrations used in treatment
experiments (table 1C). Taken together, these data demonstrate
that the uncovered combinations have a favourable safety proﬁle
in cell culture models and primary cells providing the rationale
for their further development.
DISCUSSION
There is an unmet medical need for novel strategies for the pre-
vention of HCV graft infection following LT, and a need to
develop more efﬁcient and better tolerated combination therap-
ies for chronic infection for certain patient subgroups and
patients with resistance.1 2 Many DAAs are restricted to geno-
type 1 and their use in difﬁcult-to-treat patients could be hin-
dered by signiﬁcant and potentially harmful drug–drug
interactions.7 Among the most promising DAAs are polymerase
and NS5A inhibitors, which demonstrated potent pan-genotypic
antiviral activity with a high barrier for resistance when com-
bined with SOC or RBV.45 46 Nevertheless, in vivo emergence
of resistant mutants conferring cross-resistance to polymerase
inhibitors sofosbuvir and mericitabine has been described,47 and
combination of daclatasvir with protease inhibitors was asso-
ciated with signiﬁcant viral breakthrough rates.3 37 Recent phase
III studies indicate that sofosbuvir and RBV had only limited
efﬁcacy against genotype 3 compared with SOC, with lowest
Figure 6 Combination of direct-acting antivirals (DAAs), host-targeting agents and entry inhibitors results in synergy in treatment of established
HCV infection. Huh7.5.1 cells were infected for 5 days with HCVcc prior to treatment with DAAs or alisporivir and entry inhibitors as described in
‘Materials and methods’. Synergy between (A) telaprevir and anti-CLDN1 mAb (left) or erlotinib (right), (B) daclatasvir and anti-SR-BI mAb (left) or
anti-CLDN1 mAb (right), (C) sofosbuvir and anti-CLDN1 mAb (left) or erlotinib (right), (D) alisporivir and anti-SR-BI (left) or anti-CLDN1 mAb (right)
was assessed using the Prichard and Shipman method.25
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efﬁcacy in cirrhotic patients.40 41 Thus, strong antiviral efﬁcacy
and high genetic barrier to resistance will remain key require-
ments for IFN-free regimens to avoid early treatment failure
and the optimal combination for deﬁned patient groups and
viral genotypes still needs to be deﬁned.
To address the limitations of SOC and DAAs, we evaluated
the antiviral effect of combining entry inhibitors with IFN-α,
DAAs or HTAs. Our results uncover novel combinations of
entry inhibitors and IFN-α, DAAs or HTAs highlighted by
marked synergy in vitro (ﬁgures 1–7, online supplementary
ﬁgure S1 and tables S1–S3). Antiviral activity of compounds in
the HCVcc model correlates well with clinical antiviral activity
in patients,36 and synergy was robust and signiﬁcant at IC50,
IC75 and IC90, at all concentrations tested and similar in experi-
mental prevention and treatment designs. Furthermore, we also
demonstrate evidence for a synergistic effect of the combination
of an entry inhibitor with a DAA in vivo using the human
liver-chimeric uPA/SCID mouse model (ﬁgure 9).
A challenge of current and future therapies remains the coun-
tering of the development of drug-resistant variants.1–3
Compared with the high variability of viral proteins targeted by
DAAs, the variability of host factors targeted by HTAs is low.8
Therefore, host-targeting entry inhibitors may impose a higher
genetic barrier to resistance than DAAs. Supplementary to this
concept, we and others have shown that entry inhibitors
potently inhibit highly infectious escape variants of HCV that
are resistant to host neutralising antibodies.9 10 13–15 22
Interestingly, the disease outcome for HIV-infected individuals
has signiﬁcantly improved with the development of antiretro-
viral drugs targeting different steps of the viral life cycle includ-
ing viral entry.48 Although viral variants resistant to HIV entry
inhibitors have been described, there is no evidence of cross-
resistance between different classes of antivirals.48 In contrast to
HIV, co-receptor tropism/switch has not been described for
HCV as a potential mechanism for viral escape and successful
Figure 7 Synergistic effect of combining direct-acting antivirals and entry inhibitors in treatment of HCV infection using persistently infected
DMSO-differentiated hepatoma cells. HCV-infected cell culture was established by transfecting RNA encoding wild-type HCV Luc-Jc1 into Huh7.5.1
cells. The cells were then differentiated in the presence of 1% DMSO for 5 days before treatment with the combinations of (A) telaprevir
+anti-CLDN1 mAb (left) or erlotinib (right), (B) daclatasvir+anti-SR-BI mAb (left) or anti-CLDN1 mAb (right), (C) sofosbuvir+anti-CLDN1 mAb (left) or
erlotinib (right), (D) simeprevir+erlotinib (left) or anti-CLDN1 mAb (right). HCVcc infection was assessed by luciferase activity 5 days after treatment.
Synergy was assessed using the Prichard and Shipman method.25
Figure 8 Entry inhibitors limit viral rebound from direct-acting
antiviral therapy. Persistently HCV ( Jc1) infected and
DMSO-differentiated cells described in ‘Materials and methods’ were
ﬁrst treated with 500 nM simeprevir for 8 days followed by incubation
with either 1% DMSO control medium (mock), 10 mg/mL anti-CD81
mAb or 10 mM erlotinib sequentially for another 12 days. Cells
maintained in 1% DMSO throughout the experiment were used as
control (CTRL). Viral load was assessed by HCV-speciﬁc RT-PCR every
4 days. The limit of quantiﬁcation, indicated by a dashed line, was 103
copies/mL. Means±SD from a representative experiment performed in
triplicate are shown. An asterisk indicates one out of three samples
was HCV RNA negative; two asterisks indicate two samples were HCV
RNA negative.
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antiviral therapy can deﬁnitively eradicate HCV from infected
patients. Combination of entry inhibitors with compounds tar-
geting complementary steps of the viral life cycle may open a
perspective to overcome antiviral resistance, allow shortening
treatment schedules, lower the risk for adverse effects and
reduce the doses of the single compounds.
Given that HTAs interfere with host targets, there is theoretic-
ally a greater risk of cellular toxicity than with DAAs. Host
targets CD81, SR-BI, CLDN1 and EGFR described in this study
are expressed in various tissues and play an important role in
cell adhesion, lipid metabolism or signalling. Noteworthy, the
large majority of licensed drugs in clinical use (eg, in cardiovas-
cular, inﬂammatory disease or oncology) targets host proteins
and side effects are not necessarily more pronounced than in
drugs targeting the virus.8 Indeed, the EGFR inhibitor erlotinib,
a clinically licensed drug for non-small-cell lung cancer, has a
favourable safety proﬁle and is well tolerated in lung cancer
patients.49 Moreover, clinical licensed HIV host-targeting entry
Table 1 Absent toxicity of combinations of compounds in Huh7.5.1 cells and primary human hepatocytes
Compound 1 Concentration Compound 2 Concentration Relative Huh7.5.1 viability (%) Relative PHH viability (%)
(A) Cytotoxic effects of combination therapies on Huh7.5.1 cells and PHH after 48 h
IFN-α2a 10 IU/mL Anti-CLDN1 10 mg/mL 106±11 101±2
IFN-α2b 10 IU/mL Anti-CLDN1 10 mg/mL 108±15 97±3
Telaprevir 10 mM Erlotinib 10 mM 84±21 93±5
Boceprevir 10 mM Anti-CLDN1 10 mg/mL 94±8 103±3
Simeprevir 10 mM Anti-CLDN1 10 mg/mL 104±5 97±4
Danoprevir 10 mM Anti-CLDN1 10 mg/mL 91±12 103±1
Daclatasvir 10 nM Anti-SR-BI 10 mg/mL 114±18 101±2
Mericitabine 10 mM Anti-CD81 10 mg/mL 131±22 106±5
Sofosbuvir 10 mM Anti-SR-BI 10 mg/mL 95±15 110±7
Sofosbuvir 10 mM Anti-CLDN1 10 mg/mL 93±8 97±5
Sofosbuvir 10 mM Dasatinib 10 mM 89±14 103±8
Sofosbuvir 10 mM Erlotinib 10 mM 87±15 101±4
Anti-Fas 10 mg/mL 16±2
Compound 1 Concentration Compound 2 Concentration Relative Huh7.5.1 viability (%)
(B) Cytotoxic effects of combination therapies on Huh7.5.1 cells after 5 days
Telaprevir 10 mM Anti-CLDN1 10 mg/mL 92±4
Telaprevir 10 mM Erlotinib 10 mM 89±3
Daclatasvir 10 nM Anti-SB-BI 10 mg/mL 103±16
Daclatasvir 10 nM Anti-CLDN1 10 mg/mL 106±7
Sofosbuvir 10 mM Anti-CLDN1 10 mg/mL 93±2
Sofosbuvir 10 mM Erlotinib 10 mM 91±4
Alisporivir 10 mM Anti-SR-BI 10 mg/mL 97±8
Alisporivir 10 mM Anti-CLDN1 10 mg/mL 108±6
Flavopiridol 10 mM 20±6
Compound CC50
(C) 50% cytotoxic concentrations (CC50) of entry inhibitors in Huh7.5.1 cells. Dose-dependent toxicity of entry inhibitors was measured using Prestoblue assay as described in
Materials and methods. CC50 were calculated by regression analysis
Anti-CLDN1* >1 mg/mL
Anti-CD81* >1 mg/mL
Anti-SR-BI* 789±189 mg/mL
Erlotinib† >100 mM
Dasatinib† >100 mM
Combination Relative Huh7.5.1 viability (%)
(D) Cytotoxic effects of combination therapies as described in figure 8. Cell viability was measured at the end of the experiment using Prestoblue assay as described in
Materials and methods
Telaprevir+mock 97±10
Telaprevir+anti-CLDN1 91±3
Telaprevir+erlotinib 81±4
Cytotoxic effects on Huh7.5.1 cells (A, B, C, D) and PHH (A) using the highest concentrations of each compound used in combination (IFN-α, 10 IU/mL; DAAs, 10 nM or mM; alisporivir,
10 mM; receptor-specific mAbs, 10 mg/mL and PKIs, 10 mM) were assessed by analysing the ability to metabolise MTT after 48 h (A, B), 5 days (C), or 20 days (D) as described.23–32
Anti-Fas antibody (10 mg/mL) or flavopiridol (10 mM) was used as a positive control of toxicity. Toxicity analyses of the most efficient combinations are shown. Data are presented as
relative cell viability compared with PHH or Huh7.5.1 cells cultured in the absence of compounds or solvent (=100%). Means±SD from one representative experiment performed in
triplicate are shown.
*The stock concentration of the entry inhibitors was 2 mg/mL.
†Erlotinib or dasatinib started to precipitate in the medium at the concentrations higher than 100 mM.
DAA, direct-acting antiviral; IFN, interferon; PHH, primary human hepatocyte; PKI, protein kinase inhibitor; SR-BI, scavenger receptor class B type I.
Hepatology
Xiao F, et al. Gut 2015;64:483–494. doi:10.1136/gutjnl-2013-306155 491
inhibitors do not necessarily display more adverse events than
antiretroviral drugs.48 Nevertheless, safety is an important issue
and needs to be carefully addressed for both DAAs and HTAs.
Host-targeting antibodies will need to be humanised prior to
clinical development.
A pan-genotypic, highly efﬁcient, IFN-free regimen is the
ultimate goal for HCV therapy. Compared with many DAAs
that act in genotype-dependent manner, host-targeting entry
inhibitors exhibit a broad pan-genotypic activity: examples
include CLDN1-,22 SR-BI-14 15 and CD81-speciﬁc16 17 mAbs,
ITX-5061,18 erlotinib,13 ezetimibe,12 ﬂavonoids,19 20 lectins,21
phosphorothioate oligonucleotides50 and silymarin.51 52 Thus,
combination of entry inhibitors with DAAs may deﬁne novel
options for patients with non-genotype 1 infections and simplify
treatment regimens.
Entry inhibitors are ideally suited for prevention of HCV
liver graft infection. Currently, there is no option to protect
HCV-negative grafts from reinfection while the clinical use of
hepatitis B immune globulin (a well-characterised HBV entry
inhibitor) in combination with nucleos(t)ide analogues has
essentially eliminated HBV recurrence in LT patients.5 Since
HCV entry is a key mechanism for liver graft infection,9 10 the
observed synergy between DAAs and entry inhibitors uncovers a
promising opportunity for prevention of graft infection. The
combination of host-targeting entry inhibitors with DAAs may
be particularly attractive since the high variability of HCV has
so far hampered the development of efﬁcient cross-neutralising
antienvelope antibodies.53
Interfering with HCV cell entry offers several targets at differ-
ent steps of viral entry: blocking virus–target cell interaction
during attachment, interfering with postbinding events such as
CD81-CLDN1 associations or viral fusion.8 Interestingly, com-
bination of different entry inhibitors, including CLDN1-speciﬁc
mAb and kinase inhibitors, also showed synergy on HCV entry
and infection (ﬁgure 5A). While CLDN1-speciﬁc antibodies and
PKIs both interfere with CD81-CLDN1 coreceptor interactions,
PKIs also interfere with glycoprotein-dependent viral fusion.13
This additional and complementary MOA on membrane fusion
of PKIs is most likely responsible for the synergistic effect. This
concept is conﬁrmed by the ﬁnding that combination of
anti-CD81 and anti-CLDN1 mAbs, which target a similar step
in the viral entry process, only exhibits an additive effect (ﬁgure
5A). Thus, these results deﬁne novel combinations of entry inhi-
bitors for prevention of graft infection.
Interestingly, two entry inhibitors erlotinib (targeting EGFR
and CD81-CLDN1 co-receptor associations) and ITX-5061 (tar-
geting HCV-SR-BI interactions) have reached clinical develop-
ment to determine the safety and efﬁcacy in patients with HCV
infection (ClinicalTrials.gov identiﬁer NCT01835938 and
NCT01292824). Moreover, a signiﬁcant number of compounds
tested in this study are already FDA-approved for treatment of
chronic HCV infection: telaprevir, boceprevir, sofosbuvir and
simeprevir. Erlotinib and dasatinib have been approved for
cancer treatment exhibiting a good safety proﬁle.54 It will thus
be interesting to investigate the synergistic effect of these drugs
in patients with chronic hepatitis C. Taken into account the efﬁ-
cacy, safety, pharmacokinetics, stage of development combined
with the synergy data of the various compounds (ﬁgures 1–7), our
data suggest that combinations of simeprevir34 or sofosbuvir 40
with erlotinib could be a starting point to assess synergy in rando-
mised clinical trials. Combining sofosbuvir and anti-CLDN1 or
anti-SR-BI mAb might be promising for prevention of liver graft
infection following the clinical development of the monoclonal
antibodies. Collectively, novel combinations based on synergy
uncovered in this study may widen the therapeutic arsenal
against HCV infection for prevention of liver graft infection,
treatment of difﬁcult-to-treat-patients and provide alternatives
for patients with contraindications to particular compounds of
SOC or future IFN-free regimens.
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